Morepen Laboratories

** Shares of India's Morepen Laboratories MORL.NS fall 4.8% to 41.81 rupees

** Pharma firm's Q4 consol net profit fell 22.7% y/y to 157 million rupees ($1.64 million)

** Total expenses rose about 5.7%, outpacing revenue from operations rise of 4%

** YTD, stock up nearly 1.4%

($1 = 95.7550 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

May 26 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET PROFIT 157 MILLION RUPEES

• MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET INCOME FROM OPERATIONS 4.85 BILLION RUPEES

Source text: ID:nBSE5zy8q3

Further company coverage: MORL.NS

(([email protected];))

April 17 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• USFDA CLEARS MASULKHANA API FACILITY WITH NIL FORM 483 OBSERVATIONS

• ANNOUNCES USFDA INSPECTION AT MASULKHANNA FACILITY WITH ZERO OBSERVATIONS

Source text: ID:nBSE5VDB5R

Further company coverage: MORL.NS

(([email protected];;))

** Shares of Morepen Laboratories MORL.NS up 15.1% at 45.2 rupees, set for best day since August 19, 2024

** Pharma co wins order worth 8.25 bln rupees ($90.9 mln) in contract drug manufacturing segment

** Stock rises as much as 15.7% earlier in the day

** Stock moves above its 50-day, 100-day simple moving avgs

** More than 30 mln shares traded, 15.5x their 30-day moving avg, and marking busiest day since April 24, 2025

** YTD, MORL up ~10%

($1 = 90.7500 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Feb 10 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• DEC-QUARTER CONSOL NET PROFIT 275.1 MILLION RUPEES

• DEC-QUARTER CONSOL INCOME FROM OPERATIONS 4.84 BILLION RUPEES

Further company coverage: MORL.NS

(([email protected];))

Jan 8 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES - COURT GRANTS STAY ON 1.18 BILLION RUPEES TAX DEMAND AGAINST CO

Source text: ID:nNSE7gzGQR

Further company coverage: MORL.NS

(([email protected];))

** Shares of Morepen Laboratories MORL.NS jump as much as 17% to 64 rupees, their highest level since February 6

** Pharma co announces launch of four new products - Ticapen, UdoFix, LycoMore and Acifix used for cardiovascular health, liver health, nutrition and heartburn, respectively

** MORL targets to grow formulation business to 10 billion rupees ($117.2 million) in five years from 3.25 billion rupees currently

** More than 30 mln shares traded, trading vols at 5x their 30-day avg

** Stock is down 20% so far in 2025

($1 = 85.3280 Indian rupees)

(Reporitng by Nishit Navin)

(([email protected];))

** Morepen Laboratories MORL.NS rises 7.4% to 46 rupees; set for biggest one-day pct gain in over six months

** Pharma co launches diabetes drug Empamore priced about ~90% below existing brands

** Stock set to snap five-day losing run

** More than 5.9 mln shares traded, over 1.5x the 30-day avg

** MORL loses 40% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES LTD - LAUNCHES EMPAMORE FOR DIABETES, HEART FAILURE, AND KIDNEY DISEASE

Source text: ID:nBSE6jPcgn

Further company coverage: MORL.NS

Feb 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• DEC-QUARTER NET PROFIT 226.8 MILLION RUPEES

• DEC-QUARTER INCOME FROM OPERATIONS 4.03 BILLION RUPEES

Source text: ID:nBSEbls5hn

Further company coverage: MORL.NS

(([email protected];))

Jan 15 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS

• MOREPEN LABORATORIES LTD - SLUMP SALE OF MEDICAL DEVICES EXPECTED TO COMPLETE BY SEPTEMBER 30, 2025

Source text: ID:nNSE3S5V9H

Further company coverage: MORL.NS

(([email protected];;))

Jan 14 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES LTD - APPROVES HIVING OFF MEDICAL DEVICES BUSINESS

• MOREPEN LABORATORIES - HIVING OFF MEDICAL DEVICES BUSINESS TO MOREPEN MEDTECH

Source text: ID:nNSE4M6Km8

Further company coverage: MORL.NS

(([email protected];))

Dec 27 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES LTD - TO INCORPORATE NEW SUBSIDIARY

Source text: ID:nNSEbjW8ys

Further company coverage: MORL.NS

(([email protected];))

Dec 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• DR. MOREPEN TARGETING REVENUE OF 300 MILLION RUPEES IN FIRST YEAR FROM LIGHTLIFE

• DR. MOREPEN HAS GOAL OF 1 BILLION RUPEES REVENUE OVER NEXT THREE YEARS FROM LIGHTLIFE

Further company coverage: MORL.NS

(([email protected];))

Nov 11 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES SEPT-QUARTER CONSOL NET PROFIT 348.5 MILLION RUPEES

• MOREPEN LABORATORIES SEPT-QUARTER CONSOL TOTAL INCOME 4.43 BILLION RUPEES

Source text: [ID:]

Further company coverage: MORL.NS

(([email protected];))

** Shares of Morepen Laboratories Ltd MORL.NS up 13% at 92.89 rupees, their highest since December 2001

** Around 1.9 mln shares of active pharmaceutical ingredients maker traded in 3 separate block deals, all at a premium to previous closing price of 82.22 rupees

** Overall, 64.8 mln shares traded vs 30-day avg volume of 25.8 mln shares

** Stock up ~93% so far this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Aug 12 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• JUNE-QUARTER CONSOL NET PROFIT 361.7 MILLION RUPEES

• JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 4.55 BILLION RUPEES

Further company coverage: MORL.NS

(([email protected];))

Aug 6 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• RAISES 2 BILLION RUPEES VIA QIP

Source text for Eikon: ID:nBSE4LjHM9

Further company coverage: MORL.NS

(([email protected];;))

Aug 1 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• AUTHORISED THE OPENING OF QIP ISSUE ON AUG 1

• APPROVED FLOOR PRICE FOR QIP AT 57.23 RUPEES PER SHARE

Source text for Eikon: ID:nNSE9q710P

Further company coverage: MORL.NS

(([email protected];))

May 21 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET PROFIT 287.4 MILLION RUPEES VERSUS PROFIT 82.4 MILLION RUPEES

• MOREPEN LABORATORIES MARCH-QUARTER CONSOL NET INCOME FROM OPERATIONS 4.23 BILLION RUPEES VERSUS 3.64 BILLION RUPEES

Source text for Eikon: ID:nBSE7yr18k

Further company coverage: MORL.NS

(([email protected];))

Feb 22 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• APPROVED RAISING OF FUNDS WORTH UPTO 3.5 BILLION RUPEES

Source text for Eikon: ID:nNSE4RkQzT

Further company coverage: MORL.NS

(([email protected];))

Feb 19 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• TO CONSIDER FUND RAISING

Source text for Eikon: ID:nBSE9Gdhgt

Further company coverage: MORL.NS

(([email protected];))

Morepen Laboratories Ltd MORL.NS:

• MOREPEN LABORATORIES LTD- APPROVED TRANSFER OF FORMULATION DISTRIBUTION & MARKETING BUSINESS TO MOREPEN RX

• MOREPEN LABORATORIES LTD- DEAL FOR 70.3 MILLION RUPEES

Source text for Eikon: ID:nNSE6Rk67N

Further company coverage: MORL.NS

** Shares of Morepen Laboratories MORL.NS surge as much as 14.59% to a near seven-month high of 34.95 rupees

** The pharmaceutical firm's net profit almost triples year-on-year to 145.33 mln rupees in June quarter

** Revenue jumps ~33% to 4.01 bln rupees; EBITDA nearly doubles to 260.89 mln rupees

** Co reappoints Sushil Suri as the Chairman and Managing Director for a further three-year period, effective from Oct. 20, 2023

** Relative strength index rises above 70, suggesting the stock may be overbought

** Stock most active in nearly two months, with a trading volume of 21.71 mln shares as of 12:42 p.m. IST, nearly seven times the 30-day avg - Refinitiv data

** Including Monday's gains, MORL down 11.49% in 2023 so far, compared to 22.35% rise in pharma index .NIPHARM

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

May 30 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• INDIA SUPREME COURT ORDERED STAY ON CONTEMPT PROCEEDINGS AGAINST CO, DIRECTORS PENDING BEFORE NCLT

Source text for Eikon: ID:nBSE5BBnV2

Further company coverage: MORL.NS

(([email protected];))

** Shares of Morepen Laboratories Ltd MORL.NS fall as much as 3.14% to 26.20 rupees, a three-week low

** Pharma firm reports 33% fall in consolidated net profit in March quarter to 82.4 mln rupees from 123.2 mln rupees a year earlier nFWN37D1E6

** Consolidated income from operations falls 1% to 3.64 bln rupees from 3.68 bln rupees Y/Y

** Core profit slips 27% YoY to 155.59 mln rupees; core profit margins contract to 4.27% from 5.07%

** Trading volume is 1.52 mln shares as of 12:49 p.m. IST, half the 30-day avg - Refintiv data

($1 = 81.7800 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

May 16 (Reuters) - Morepen Laboratories Ltd MORL.NS:

• MARCH-QUARTER CONSOL NET PROFIT 82.4 MILLION RUPEES VERSUS 123.2 MILLION RUPEES

• MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 3.64 BILLION RUPEES VERSUS 3.68 BILLION RUPEES

Further company coverage: MORL.NS

(([email protected];))